UroGen Pharma
URGN
URGN
71 hedge funds and large institutions have $469M invested in UroGen Pharma in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
+11
Holders Change %
+18.33%
% of All Funds
1.63%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
18
Increased
23
Reduced
19
Closed
7
Calls
–
Puts
$359K
Net Calls
-$359K
Net Calls Change
-$359K
Top Buyers
1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.88M |
2 |
WCM
Wildcat Capital Management
New York
|
+$5.86M |
3 |
DG
Delek Group
Herzliya,
Israel
|
+$4.68M |
4 |
Man Group
London,
United Kingdom
|
+$4.03M |
5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$3.56M |
Top Sellers
1 |
![]()
Fidelity Investments
Boston,
Massachusetts
|
-$7.11M |
2 |
DP
DSAM Partners
London,
United Kingdom
|
-$6.35M |
3 |
Renaissance Technologies
New York
|
-$4.66M |
4 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$2.96M |
5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$957K |